Jornal de cirurgia ocular e de catarata Acesso livre

Abstrato

Role of laser photocoagulation and intravitreal Injection of Lucentis in the treatment of retinopathy of prematurity

Waseem Jafri

Purpose: To determine the effect of laser photocoagulation with or without intravitreal Lucentis injection in the treatment of retinopathy of prematurity (ROP). Methods: 68 eyes of 34 premature babies were treated for ROP in 44 months. 54 eyes received laser. 12 eyes received laser and intravitreal Lucentis injection. 2 eyes received only intravitreal Lucentis injection. Retinopathy of immatureness (ROP) may be a vasoproliferative disorder touching the retinas of premature infants. The screening, treatment, and pathophysiologic understanding of ROP have dramatically evolved over the past four decades. 2 landmark studies, Cryotherapy for ROP (CRYO-ROP)1 in one988 and Early Treatment for ROP (ETROP)2 in 2004 have served because the stepping stones for establishing treatment tips with relevancy threshold and prethreshold kind ROP. Most recently, however, intravitreal antiâ??vascular epithelial tissue protein (anti-VEGF) agents for ROP have received abundant attention within the health profession as a possible various. reported blessings of anti-VEGF pharmacotherapy over optical device surgery embody reduced treatment time with less stress on the newborn, swift resolution of and malady with prompt regression of ROP, potential of any membranel vascular development with no ablation of the peripheral avascular retina, lower risk of shortsightedness, and improved treatment outcomes for zone I ROP or AP-ROP.3–5 Anti-VEGF may additionally be the sole treatment choice in cases of media opacity or vitreous hemorrhage once Associate in Nursing too little read is gift for optical device surgery. One of the biggest anti-VEGF studies in ROP to this point, the BEAT-ROP (Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity) trial,5 found that bevacizumab (Avastin; Genentech INC, South San Francisco, California, USA) will halt the progression of severe ROP, revert pathologic angiogenic changes, and induce the progression of physiological intraretinal vasculature. Of note, BEAT-ROP was the primary prospective study to analyze anti-VEGF use for ROP at time once the preponderance of literature was within the style of retrospective case reports and series.